Eli Lilly misses sales estimates as top-seller Trulicity disappoints

Eli Lilly and Co's quarterly sales missed Wall Street estimates on Wednesday due to a weaker-than-expected performance of its diabetes drug Trulicity because of lower realized prices, sending shares down 3%.